Mersana Therapeutics Stock Price, News & Analysis (NASDAQ:MRSN)

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics Inc (NASDAQ:MRSN) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.38) by $0.02. The company earned $0.20 million during the quarter, compared to the consensus estimate of $1.08 million. Mersana Therapeutics had a negative net margin of 77.78% and a negative return on equity of 51.13%. View Mersana Therapeutics' Earnings History.

Mersana Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Mersana Therapeutics.

5 brokers have issued 1 year price targets for Mersana Therapeutics' shares. Their forecasts range from $12.00 to $14.00. On average, they expect Mersana Therapeutics' stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 606.5% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.

News coverage about MRSN stock has been trending extremely negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mersana Therapeutics earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Mersana Therapeutics.

Mersana Therapeutics saw a drop in short interest in September. As of September 30th, there was short interest totalling 632,700 shares, a drop of 9.3% from the August 30th total of 697,900 shares. Based on an average trading volume of 239,800 shares, the days-to-cover ratio is currently 2.6 days. Approximately 1.8% of the company's stock are short sold. View Mersana Therapeutics' Current Options Chain.

Some companies that are related to Mersana Therapeutics include Neptune Wellness Solutions (NEPT), Molecular Templates (MTEM), Atreca (BCEL), OptiNose (OPTN), Ardelyx (ARDX), ProQR Therapeutics (PRQR), Kindred Biosciences (KIN), CytomX Therapeutics (CTMX), Protagonist Therapeutics (PTGX), Avid Bioservices (CDMO), Recro Pharma (REPH), Theratechnologies (THERF), Rigel Pharmaceuticals (RIGL), Urovant Sciences (UROV) and Dynavax Technologies (DVAX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include Dynavax Technologies (DVAX), Eyepoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Coherus Biosciences (CHRS), Clearside Biomedical (CLSD), Exelixis (EXEL), ImmunoGen (IMGN), Immunomedics (IMMU), Kala Pharmaceuticals (KALA) and Madrigal Pharmaceuticals (MDGL).

(MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (25.02%). Company insiders that own Mersana Therapeutics stock include Enterprise Associates 14 New and Timothy B Lowinger. View Institutional Ownership Trends for Mersana Therapeutics.

MRSN stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC. View Insider Buying and Selling for Mersana Therapeutics.

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MRSN stock can currently be purchased for approximately $1.84.

Mersana Therapeutics has a market capitalization of $87.97 million and generates $10.59 million in revenue each year. The company earns $-64,260,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe.View Additional Information About Mersana Therapeutics.

The official website for Mersana Therapeutics is http://www.mersana.com/.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]